Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.64 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.64 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.64 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31212507 | 0.89 | PTGER4 (0.77) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL1261128 | 0.89 | PTGER4 (0.77) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL6053663 | 0.87 | PTGER4 (0.81) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL8479912 | 0.87 | PTGER4 (0.70) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL29277857 | 0.85 | IAPP (0.51) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL4153503 | 0.85 | PTGER4 (0.62) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL28638330 | 0.83 | ABL1 (0.54) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL71453 | 0.83 | PTGER4 (0.68) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL7601609 | 0.82 | AKR1B1 (0.57) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL26680676 | 0.82 | PTGER4 (0.77) | PTGER4PTGER3PTGER1PTGER2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | PTGER4 443/4885PTGER3 76/4885PTGER1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.